Latest Headlines

Latest Headlines

Alnylam pockets $7M from Genzyme as RNAi program hums along

Gene-silencing expert Alnylam is $7 million richer thanks to some positive mid-stage results for its Genzyme-licensed RNA-interference candidate, and the Cambridge, MA, company is looking to be the first to market with the difficult-to-deliver class of treatments.

New York Stem Cell Foundation, NIH partner to study rare diseases

In an effort to better understand diseases that have long eluded diagnosis, the New York Stem Cell Foundation Research Institute is partnering with the National Institutes of Health's Undiagnosed Diseases Program to create cell models of rare medical conditions.

Indian CROs leap into U.S. with joint venture

Three of India's biggest CROs are joining forces to cash in on U.S. demand for outsourced drug services, launching a combined venture called Axcellerate Pharma.

Pharmacyclics, J&J pick Catalent for blockbuster cancer drug

Pharmacyclics and Johnson & Johnson are riding high on an accelerated approval for the blockbuster hopeful Imbruvica, and now they've tapped Catalent to aid in commercial manufacturing and ongoing clinical trials for the cancer drug.

Covance taps NeoGenomics for cancer trial diagnostics

Global CRO Covance has struck up a deal to expand its diagnostics capabilities in oncology trials, partnering with NeoGenomics to bolster its anatomic pathology and specialty lab testing.

Avalon jumpstarts first biotech in $500M GlaxoSmithKline portfolio deal

Avalon Ventures is kick-starting the first biotech enterprise in its half-billion dollar portfolio deal with GlaxoSmithKline, launching a startup named Sitari Pharmaceuticals which will pursue research work out of Stanford University with an eye to developing a new drug for celiac disease.

Vietnam taps Quintiles to up its stake in global trials

The Vietnamese government is looking to boost its share of the world's clinical research market, signing a deal with CRO giant Quintiles to get the ball rolling.

Eli Lilly, Project A.L.S. forge preclinical drug discovery pact

Eli Lilly and the nonprofit Project A.L.S. are teaming up to boost the pipeline of potential drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig' disease.

Pfizer, GlaxoSmithKline forge cancer alliance in combo melanoma trial pact

Combination cancer therapies are all the rage these days in the oncology field. Now two of the giant players in the cancer R&D arena have decided to match their top prospects to see if they can make a bigger impact on melanoma.

Unilife signs $40M deal to supply Hikma with prefilled syringes

Unilife took another big step this week, signing a long-term contract agreement with generics maker Hikma Pharmaceuticals to use Unilife's injectable technology and netting up to $40 million in the process.